WS16.4 Treatment algorithm for vitamin D deficiency – A review a year on  by Pandya, S. et al.
S32 Workshop 16. Nutrition matters Oral Presentations
WS16.1 Treatment of early diagnosed CFRD with oral drugs versus
insulin: An open prospective randomized study
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Objective: CFRD is the most frequent comorbidity in CF. One reason for the
recommendation to use Insulin as ﬁrst line treatment is the lack of data supporting
the use of oral anti-diabetic drugs. Nevertheless around 10% of all patients with CFRD
are treated with oral drugs.
Method: We initiated a multi-centres trail (NCT 00662714), enrolling patients identi-
ﬁed by screening for CFRD. In the study the effects of 3 daily insulin injections were
compared to oral treatment with Repaglinide in a RCT over two years. The primary
outcome parameter was HbA1c as a marker of glycaemic control. Secondary outcome
parameters were change in pulmonary function (FEV1%pred) and change in BMI-Z-
score.
73 patients with newly diagnosed CFRD were randomised. Age (mean±SD) 22.2±8.8
years, BMI-Z-score −0.74±1.1; HbA1c 6.5±0.8%; FEV1 66.9±23.5%pred.
Treatment effects after 1 and 2 years
Year Treatment Delta HbA1c
(mean±SD)
FEV1%pred.
(mean±SD)
BMI-Z-score
(mean±SD)
1 Repaglidine 0.19±0.64 −2.7±8.6 −0.15±0.36*
Insulin −0.10±1.23 −1.7±10.8 0.12±0.44
2 Repaglidine 0.16±0.74 −3.2±6.1 −0.21±0.59
Insulin −0.24±1.32 −3.2±10.4 0.002±0.42
*p< 0.05 repaglinide vs Insulin.
After 1 year of treatment, BMI-Z-score was better with insulin but this did not persist
after two years. There was no inferiority of the oral treatment in neither the primary
nor the secondary outcome parameter after two years of treatment.
Conclusion: In this group of newly diagnosed patients with CFRD, the oral treatment
with Repaglinide was a safe and effective therapeutic option. This is important because
in this age group there are many challenges (e.g. start with a job) and the additional
burden of insulin treatment might be postponed for at least two years.
Supported by: German CF Foundation, Vaincre la Mucoviscidose and NovoNordisk.
WS16.2 Glucose handling in CF − Implications for the diagnosis and
screening of CFRD
D. Nazareth1, P. Dyce1, K. Mohan1, M. Walshaw1. 1Liverpool Adult CF Unit,
Liverpool, United Kingdom
Introduction: The OGTT, based on the WHO criteria, is the recommended
diagnostic test to screen for diabetes in CF. However the glucose response through
the day has not been evaluated in CF subjects, who have a ‘normal’ standard OGTT.
To study this further, we compared the diurnal response to a glucose a load in 13
pancreatic insufﬁcient CF subjects with 10 healthy (age, BMI matched) controls.
Method: Subjects underwent a standard validated mixed meal test (75g CHO) at
0800, 1300 and 1800 hours on the same day. Blood glucose levels were measured
over 120 minutes for each test meal. The area under the curve was calculated for
the initial 30 (AUC30) and total 120 (AUC120) minutes of each test.
Results: See Table [Mean (SD)]. CF subjects had signiﬁcantly higher AUC30
(morning and evening) and AUC120 (all times in the day) compared to controls.
Although there was some diminution in glucose levels in CF patients during the
afternoon, they increased again later in the day which was not seen in control
subjects.
Conclusions: CF subjects have higher glucose levels not only in the morning but
throughout the day. This has important clinical implications for the diagnosis of
CFRD as more physiological tests that capture this effect should be used when
assessing the glycaemic status CF patients.
Table. Diurnal glucose handling
0800 h 1300 h 1800 h
AUC30 AUC120 AUC30 AUC120 AUC30 AUC120
Controls 151±29 564±120 155±17 605±69 160±21 638±101
CF 182±24 779±118 163±21* 638±85D 181±16W 806±132^
Within group: vs morning: *p = 0.004, Dp = 0.0009; vs afternoon: Wp = 0.03, ^p = 0.003.
Reference(s)
[1] Jarrett, R. BMJ 1972; 1(5794): 199–201.
WS16.3 Vitamin D supplementation in patients with cystic ﬁbrosis:
A pilot randomized controlled trial
T. Pincikova1, M. Flodstro¨m-Tullberg2, L. Hjelte1. 1Karolinska Institutet,
Stockholm CF Center, Stockholm, Sweden; 2Karolinska Institutet, Center for
Infectious Medicine, Stockholm, Sweden
Objectives: Vitamin D (vit D) insufﬁciency is frequent in CF patients. Evidence
of beneﬁt of vit D in CF is weak. The effect of vit D on calcium homeostasis,
inﬂammation, lung function and quality of life in CF patients was investigated in a
pilot trial (ClinicalTrials.gov:NCT01321905).
Methods: Patients (16) were randomized to vit D2 or vit D3 or to serve as controls.
The initial weekly dose of 35000/50000 IU (children/adults) was individually
adjusted by monitoring s25OHD. Three months of intervention were followed by
two of wash-out.
Results: S25OHD correlated with total vit D dose/kg BW, and with sun exposure.
Patients on vit D3 had a transitory increase in albumin-corrected calcium at 1-week
visit and higher s25OHD compared with controls at 3-months visit. In this group,
serum IgA increased, eosinophils decreased and there was a tendency for decrease
in IL-6 and CRP. Patients receiving vit D2 downregulated serum total IgG and
upregulated lymphocytes. Patients reaching s25OHD 111–129 nmol/l increased their
PEF, FEF25% and CFQ-R self-reported scores in the Emotion, Body, Weight
and Respiratory domains. The CFQ-R parent-reported score for the Respiratory
domain was higher in children reaching s25OHD 92−97 nmol/L compared with
those reaching s25OHD 58−82 nmol/l. Accordingly, s25OHD correlated positively
with FEV%, FEF50%, FEF75%, and CFQ-R scores for the Emotion and Respiratory
domains. No vit D toxicity was seen.
Conclusion: Our results suggest that vit D supplementation in CF patients is safe
and beneﬁcial. Its effect may be clinically relevant when s25OHD is increased to
111–129 nmol/L, with positive impact on inﬂammation, lung function and quality
of life.
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Introduction: Fat soluble vitamins are poorly absorbed in CF, even in those with
adequate pancreatic enzyme replacement, such that most patients have low serum
levels and require supplementation. This is particularly important with vitamin D,
where low levels are associated with poor bone mineralisation. However the correct
amount of supplementation can vary, so to overcome this we developed and
published a treatment algorithm (ECFC 2012). We wished to assess the efﬁcacy
of this tool in correcting vitamin D levels in our large adult CF clinic.
Method: We checked vitamin 25OHD levels pre and post treatment, following the
introduction of the algorithm.
Results: See the table.
Vitamin 25OHD Levels pre and post treatment
Treatment Regime Treatment period
(months),
25OHD Levels (nmol/l),
mean (range)
P value
Mean (range) pre
treatment
post
treatment
50,000iu Cholecalciferol
weekly for 8 wks, 26 pts
5 (1−12) 17.6
(5.8−28.6)
78.6
(9.9−177.7)
<0.0001
Calcichew D3 forte b.d.,
32 pts
6 (1−12) 37.7
(20.8−51.5)
57.3
(18.5−100.9)
<0.0001
Conclusion:We have shown that the use of our treatment algorithm has signiﬁcantly
improved vitamin D levels in patients with insufﬁcient or deﬁcient vitamin D status.
Our aim is to continue with this approach to ensure that vitamin D levels are
maintained above 50 nmol/l throughout the patients’ lifetime.
